This reflects growing consumer sophistication and recognition of GLP-1s as a drug category much like the evolution from Prozac to SSRIs. Why This Matters for Our Clients The shift to GLP-1 isnt just about trends it offers relief from legal and marketing challenges
Andrew Gostine Andrew Gostine, MD, MBA, is an accomplished healthcare professional, passionate about leveraging artificial intelligence in the clinical setting
Market your ability to help navigate the options not just offer a single product
23 Animal studies have demonstrated neuroprotective effects associated with GLP-1RA use in Alzheimer and Parkinson disease, stroke, and ocular hypertension
L., Montelius, C., stbring, K., Nilsson, S., & Hkansson, M
Christensen M, Vedtofte L, Holst JJ, Vilsbll T, Knop FK (2011) Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans